@文章{信息:doi/10.2196/18269，作者="马金飞邹金飞，紫豪帕佐，Emmanuel Eric和Moutari, Salissou和Liu, Ye和Jin, Feng"，标题="国家癌症综合网络-乳腺癌患者癌症治疗功能评估-乳腺癌症状指数(NFBSI-16)问卷的论文版和网络版比较分析:随机交叉研究"，期刊="JMIR Med Inform"，年="2021"，月="3"，日="2"，卷="9"，数="3"，页数="e18269"，关键词="乳腺癌;NFBSI-16;patient-reported结果;再现性;两次试验法的可靠性;背景:乳腺癌仍然是中国和全球女性中最常见的肿瘤。在研究和临床肿瘤学环境中与健康相关的问卷评估已经得到重视。国家综合癌症网络-癌症治疗功能评估-乳腺癌症状指数(NFBSI-16)是一个快速和强大的工具，用于临床和研究目的，帮助评估乳腺癌患者的疾病或治疗相关症状，包括身体和情绪。个人智能手机的普及为管理问卷提供了一种潜在的基于网络的方法; however, the reliability of the NFBSI-16 in electronic format has not been assessed. Objective: This study aimed to assess the reliability of a web-based NFBSI-16 questionnaire in breast cancer patients undergoing systematic treatment with a prospective open-label randomized crossover study design. Methods: We recruited random patients with breast cancer under systematic treatment from the central hospital registry to complete both paper- and web-based versions of the questionnaires. Both versions of the questionnaires were self-assessed. Patients were randomly assigned to group A (paper-based first and web-based second) or group B (web-based first and paper-based second). A total of 354 patients were included in the analysis (group A: n=177, group B: n=177). Descriptive sociodemographic characteristics, reliability and agreement rates for single items, subscales, and total score were analyzed using the Wilcoxon test. The Lin concordance correlation coefficient (CCC) and Spearman and Kendall $\tau$ rank correlations were used to assess test-retest reliability. Results: Test-retest reliability measured with CCCs was 0.94 for the total NFBSI-16 score. Significant correlations (Spearman $\rho$) were documented for all 4 subscales---Disease-Related Symptoms Subscale--Physical ($\rho$=0.93), Disease-Related Symptoms Subscale--Emotional ($\rho$=0.85), Treatment Side Effects Subscale ($\rho$=0.95), and Function and Well-Being Subscale ($\rho$=0.91)---and total NFBSI-16 score ($\rho$=0.94). Mean differences of the test and retest were all close to zero (≤0.06). The parallel test-retest reliability of subscales with the Wilcoxon test comparing individual items found GP3 (item 5) to be significantly different (P=.02). A majority of the participants in this study (255/354, 72.0{\%}) preferred the web-based over the paper-based version. Conclusions: The web-based version of the NFBSI-16 questionnaire is an excellent tool for monitoring individual breast cancer patients under treatment, with the majority of participants preferring it over the paper-based version. ", issn="2291-9694", doi="10.2196/18269", url="https://medinform.www.mybigtv.com/2021/3/e18269", url="https://doi.org/10.2196/18269", url="http://www.ncbi.nlm.nih.gov/pubmed/33650978" }